Survival outcomes from the quazar AML-001 trial with oral azacitidine for patients with acute myeloid leukemia in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis

Category Primary study
ConferenceHemaSphere
Year 2021
This article has no abstract
Epistemonikos ID: 67e88589ff595ed9283957bc78054b1ce3f6b1c5
First added on: Apr 30, 2026